-
1
-
-
0004171473
-
Scale for the Assessment of Negative Symptoms (SANS)
-
University of Iowa Iowa City,IA
-
Andreasen, N.C., Scale for the Assessment of Negative Symptoms (SANS). 1983, University of Iowa, Iowa City,IA.
-
(1983)
-
-
Andreasen, N.C.1
-
2
-
-
0004171473
-
Scale for the Assessment of Positive Symptoms (SAPS)
-
University of Iowa Iowa City,IA
-
Andreasen, N.C., Scale for the Assessment of Positive Symptoms (SAPS). 1984, University of Iowa, Iowa City,IA.
-
(1984)
-
-
Andreasen, N.C.1
-
3
-
-
84974793861
-
Grading quality of evidence and strength of recommendations
-
Atkins, D., Best, D., Briss, P.A., Eccles, M., Falck-Ytter, Y., Flottorp, S., et al. Grading quality of evidence and strength of recommendations. BMJ, 328, 2004, 1490.
-
(2004)
BMJ
, vol.328
, pp. 1490
-
-
Atkins, D.1
Best, D.2
Briss, P.A.3
Eccles, M.4
Falck-Ytter, Y.5
Flottorp, S.6
-
4
-
-
79951955198
-
GRADE guidelines: 3. Rating the quality of evidence
-
Balshem, H., Helfand, M., Schunemann, H.J., Oxman, A.D., Kunz, R., Brozek, J., et al. GRADE guidelines: 3. Rating the quality of evidence. J. Clin. Epidemiol. 64 (2011), 401–406.
-
(2011)
J. Clin. Epidemiol.
, vol.64
, pp. 401-406
-
-
Balshem, H.1
Helfand, M.2
Schunemann, H.J.3
Oxman, A.D.4
Kunz, R.5
Brozek, J.6
-
5
-
-
78650664657
-
Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic
-
Citrome, L., Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin. Schizophrenia Relat. Psychoses 4 (2011), 251–257.
-
(2011)
Clin. Schizophrenia Relat. Psychoses
, vol.4
, pp. 251-257
-
-
Citrome, L.1
-
6
-
-
23944456070
-
Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement
-
Citrome, L., Volavka, J., Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. J. Clin. Psychiatr. 66 (2005), 1073–1074.
-
(2005)
J. Clin. Psychiatr.
, vol.66
, pp. 1073-1074
-
-
Citrome, L.1
Volavka, J.2
-
7
-
-
65349112410
-
Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials
-
Correll, C.U., Rummel-Kluge, C., Corves, C., Kane, J.M., Leucht, S., Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr. Bull. 35 (2009), 443–457.
-
(2009)
Schizophr. Bull.
, vol.35
, pp. 443-457
-
-
Correll, C.U.1
Rummel-Kluge, C.2
Corves, C.3
Kane, J.M.4
Leucht, S.5
-
8
-
-
85019175108
-
Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls
-
Correll, C.U., Solmi, M., Veronese, N., Bortolato, B., Rosson, S., Santonastaso, P., et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatr. 16 (2017), 163–180.
-
(2017)
World Psychiatr.
, vol.16
, pp. 163-180
-
-
Correll, C.U.1
Solmi, M.2
Veronese, N.3
Bortolato, B.4
Rosson, S.5
Santonastaso, P.6
-
9
-
-
84865253275
-
Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis
-
De Hert, M., Yu, W., Detraux, J., Sweers, K., van Winkel, R., Correll, C.U., Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 26 (2012), 733–759.
-
(2012)
CNS Drugs
, vol.26
, pp. 733-759
-
-
De Hert, M.1
Yu, W.2
Detraux, J.3
Sweers, K.4
van Winkel, R.5
Correll, C.U.6
-
11
-
-
0033934949
-
Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis
-
Duval, S., Tweedie, R., Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56 (2000), 455–463.
-
(2000)
Biometrics
, vol.56
, pp. 455-463
-
-
Duval, S.1
Tweedie, R.2
-
12
-
-
0030922816
-
Bias in meta-analysis detected by a simple, graphical test
-
Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
-
(1997)
BMJ
, vol.315
, pp. 629-634
-
-
Egger, M.1
Davey Smith, G.2
Schneider, M.3
Minder, C.4
-
13
-
-
85027887125
-
Efficacy and safety of lurasidone in adolescents with schizophrenia: a 6-Week, randomized placebo-controlled study
-
Goldman, R., Loebel, A., Cucchiaro, J., Deng, L., Findling, R.L., Efficacy and safety of lurasidone in adolescents with schizophrenia: a 6-Week, randomized placebo-controlled study. J. Child Adolesc. Psychopharmacol. 27 (2017), 516–525.
-
(2017)
J. Child Adolesc. Psychopharmacol.
, vol.27
, pp. 516-525
-
-
Goldman, R.1
Loebel, A.2
Cucchiaro, J.3
Deng, L.4
Findling, R.L.5
-
14
-
-
85041427492
-
Effect of adjunctive ranitidine for antipsychotic-induced weight gain: a systematic review of randomized placebo-controlled trials
-
Gu, X.J., Chen, R., Sun, C.H., Zheng, W., Yang, X.H., Wang, S.B., et al. Effect of adjunctive ranitidine for antipsychotic-induced weight gain: a systematic review of randomized placebo-controlled trials. J. Int. Med. Res. 46 (2018), 22–32.
-
(2018)
J. Int. Med. Res.
, vol.46
, pp. 22-32
-
-
Gu, X.J.1
Chen, R.2
Sun, C.H.3
Zheng, W.4
Yang, X.H.5
Wang, S.B.6
-
15
-
-
0000238671
-
Clinical global impression scale. In ECDEU assessment manual for psychopharmacology, revised edn
-
W. Guy
-
Guy, W.A., Clinical global impression scale. In ECDEU assessment manual for psychopharmacology, revised edn. Guy, W., (eds.) US Department of Health, Education and Welfare, ADAMHA, NIMH Psychopharmacology Research Branch, 1976, 218–222.
-
(1976)
US Department of Health, Education and Welfare, ADAMHA, NIMH Psychopharmacology Research Branch
, pp. 218-222
-
-
Guy, W.A.1
-
16
-
-
84887346660
-
Cochrane handbook for Systematic Reviews of Interventions
-
John Wiley & Sons,Ltd Chichester, UK
-
Higgins, J., Higgins, J., Cochrane handbook for Systematic Reviews of Interventions. 2008, John Wiley & Sons,Ltd, Chichester, UK.
-
(2008)
-
-
Higgins, J.1
Higgins, J.2
-
17
-
-
0037098199
-
Quantifying heterogeneity in a meta-analysis
-
Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat. Med. 21 (2002), 1539–1558.
-
(2002)
Stat. Med.
, vol.21
, pp. 1539-1558
-
-
Higgins, J.P.1
Thompson, S.G.2
-
18
-
-
77953753014
-
Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity
-
Ishibashi, T., Horisawa, T., Tokuda, K., Ishiyama, T., Ogasa, M., Tagashira, R., et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J. Pharmacol. Exp. Therapeut. 334 (2010), 171–181.
-
(2010)
J. Pharmacol. Exp. Therapeut.
, vol.334
, pp. 171-181
-
-
Ishibashi, T.1
Horisawa, T.2
Tokuda, K.3
Ishiyama, T.4
Ogasa, M.5
Tagashira, R.6
-
19
-
-
0029914622
-
Assessing the quality of reports of randomized clinical trials: is blinding necessary?
-
Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, D.J., Gavaghan, D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Contr. Clin. Trials 17 (1996), 1–12.
-
(1996)
Contr. Clin. Trials
, vol.17
, pp. 1-12
-
-
Jadad, A.R.1
Moore, R.A.2
Carroll, D.3
Jenkinson, C.4
Reynolds, D.J.5
Gavaghan, D.J.6
-
20
-
-
0023606101
-
The positive and negative syndrome scale (PANSS) for schizophrenia
-
Kay, S.R., Fiszbein, A., Opler, L.A., The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987), 261–276.
-
(1987)
Schizophr. Bull.
, vol.13
, pp. 261-276
-
-
Kay, S.R.1
Fiszbein, A.2
Opler, L.A.3
-
21
-
-
85048533946
-
(lurasidone HCl) Tablets US Prescribing Information
-
Latuda, (lurasidone HCl) Tablets US Prescribing Information. 2012 http://www.latuda.com/LatudaPrescribingInformation.pdf.
-
(2012)
-
-
Latuda1
-
22
-
-
58049157203
-
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
-
Leucht, S., Corves, C., Arbter, D., Engel, R.R., Li, C., Davis, J.M., Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373 (2009), 31–41.
-
(2009)
Lancet
, vol.373
, pp. 31-41
-
-
Leucht, S.1
Corves, C.2
Arbter, D.3
Engel, R.R.4
Li, C.5
Davis, J.M.6
-
23
-
-
60349086480
-
A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia
-
Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatr. 166 (2009), 152–163.
-
(2009)
Am. J. Psychiatr.
, vol.166
, pp. 152-163
-
-
Leucht, S.1
Komossa, K.2
Rummel-Kluge, C.3
Corves, C.4
Hunger, H.5
Schmid, F.6
-
24
-
-
84875255343
-
Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial
-
Loebel, A., Cucchiaro, J., Sarma, K., Xu, L., Hsu, C., Kalali, A.H., et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr. Res. 145 (2013), 101–109.
-
(2013)
Schizophr. Res.
, vol.145
, pp. 101-109
-
-
Loebel, A.1
Cucchiaro, J.2
Sarma, K.3
Xu, L.4
Hsu, C.5
Kalali, A.H.6
-
25
-
-
84921057771
-
Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies
-
Loebel, A., Cucchiaro, J., Silva, R., Mao, Y., Xu, J., Pikalov, A., et al. Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies. Eur. Psychiatr. 30 (2015), 26–31.
-
(2015)
Eur. Psychiatr.
, vol.30
, pp. 26-31
-
-
Loebel, A.1
Cucchiaro, J.2
Silva, R.3
Mao, Y.4
Xu, J.5
Pikalov, A.6
-
26
-
-
85007591469
-
Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study
-
Loebel, A., R S, R G, K W, J C, L C, et al. Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study. J. Clin. Psychiatr. 77 (2016), 1672–1680.
-
(2016)
J. Clin. Psychiatr.
, vol.77
, pp. 1672-1680
-
-
Loebel, A.1
R, S.2
R, G.3
K, W.4
J, C.5
L, C.6
-
27
-
-
80052477010
-
Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study
-
Meltzer, H.Y., J C, R S, M O, D P, J X, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am. J. Psychiatr. 168 (2011), 957–967.
-
(2011)
Am. J. Psychiatr.
, vol.168
, pp. 957-967
-
-
Meltzer, H.Y.1
J, C.2
R, S.3
M, O.4
D, P.5
J, X.6
-
28
-
-
69149107165
-
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
-
w64
-
Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 151 (2009), 264–269 w64.
-
(2009)
Ann. Intern. Med.
, vol.151
, pp. 264-269
-
-
Moher, D.1
Liberati, A.2
Tetzlaff, J.3
Altman, D.G.4
-
29
-
-
67649222011
-
Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial
-
Nakamura, M., Ogasa, M., Guarino, J., Phillips, D., Severs, J., Cucchiaro, J., et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J. Clin. Psychiatr. 70 (2009), 829–836.
-
(2009)
J. Clin. Psychiatr.
, vol.70
, pp. 829-836
-
-
Nakamura, M.1
Ogasa, M.2
Guarino, J.3
Phillips, D.4
Severs, J.5
Cucchiaro, J.6
-
30
-
-
84995356823
-
Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies
-
Nasrallah, H.A., Cucchiaro, J.B., Mao, Y., Pikalov, A.A., Loebel, A.D., Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectr. 20 (2015), 140–147.
-
(2015)
CNS Spectr.
, vol.20
, pp. 140-147
-
-
Nasrallah, H.A.1
Cucchiaro, J.B.2
Mao, Y.3
Pikalov, A.A.4
Loebel, A.D.5
-
31
-
-
84875270413
-
Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study
-
Nasrallah, H.A., Silva, R., Phillips, D., Cucchiaro, J., Hsu, J., Xu, J., et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J. Psychiatr. Res. 47 (2013), 670–677.
-
(2013)
J. Psychiatr. Res.
, vol.47
, pp. 670-677
-
-
Nasrallah, H.A.1
Silva, R.2
Phillips, D.3
Cucchiaro, J.4
Hsu, J.5
Xu, J.6
-
32
-
-
84873710953
-
Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study
-
Ogasa, M., Kimura, T., Nakamura, M., Guarino, J., Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology 225 (2013), 519–530.
-
(2013)
Psychopharmacology
, vol.225
, pp. 519-530
-
-
Ogasa, M.1
Kimura, T.2
Nakamura, M.3
Guarino, J.4
-
33
-
-
0000503515
-
The brief psychiatric rating-scale
-
Overall, J.E., Gorham, D.R., The brief psychiatric rating-scale. Psychol. Rep. 10 (1962), 799–812.
-
(1962)
Psychol. Rep.
, vol.10
, pp. 799-812
-
-
Overall, J.E.1
Gorham, D.R.2
-
34
-
-
85029908541
-
Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders
-
Pompili, M., Verzura, C., Trovini, G., Buscajoni, A., Falcone, G., Naim, S., et al. Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders. Expet Opin. Drug Saf. 17 (2018), 197–205.
-
(2018)
Expet Opin. Drug Saf.
, vol.17
, pp. 197-205
-
-
Pompili, M.1
Verzura, C.2
Trovini, G.3
Buscajoni, A.4
Falcone, G.5
Naim, S.6
-
35
-
-
84998065445
-
A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia
-
Potkin, S.G., Kimura, T.,J.G., A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia. Ther. Adv. Psychopharmacol. 5 (2015), 322–331.
-
(2015)
Ther. Adv. Psychopharmacol.
, vol.5
, pp. 322-331
-
-
Potkin, S.G.1
Kimura, T.J.G.2
-
36
-
-
33746341926
-
The file drawer problem and tolerance for null results
-
Rosenthal, R., The file drawer problem and tolerance for null results. Psychol. Bull. 86 (1979), 638–641.
-
(1979)
Psychol. Bull.
, vol.86
, pp. 638-641
-
-
Rosenthal, R.1
-
37
-
-
22144432283
-
A systematic review of the prevalence of schizophrenia
-
Saha, S., Chant, D., Welham, J., McGrath, J., A systematic review of the prevalence of schizophrenia. PLoS Med., 2, 2005, e141.
-
(2005)
PLoS Med.
, vol.2
, pp. e141
-
-
Saha, S.1
Chant, D.2
Welham, J.3
McGrath, J.4
-
38
-
-
84958753867
-
Serotonin transporter gene polymorphism in eating disorders: data from a new biobank and meta-analysis of previous studies
-
Solmi, M., Gallicchio, D., Collantoni, E., Correll, C.U., Clementi, M., Pinato, C., et al. Serotonin transporter gene polymorphism in eating disorders: data from a new biobank and meta-analysis of previous studies. World J. Biol. Psychiatr. 17 (2016), 244–257.
-
(2016)
World J. Biol. Psychiatr.
, vol.17
, pp. 244-257
-
-
Solmi, M.1
Gallicchio, D.2
Collantoni, E.3
Correll, C.U.4
Clementi, M.5
Pinato, C.6
-
39
-
-
84946741626
-
The incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-analysis
-
Thomas, J.E., Caballero, J., Harrington, C.A., The incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-analysis. Curr. Neuropharmacol. 13 (2015), 681–691.
-
(2015)
Curr. Neuropharmacol.
, vol.13
, pp. 681-691
-
-
Thomas, J.E.1
Caballero, J.2
Harrington, C.A.3
-
40
-
-
85018526695
-
Schizophrenia
-
Van, O.J., Kapur, S., Schizophrenia. Lancet 374 (2009), 41–42.
-
(2009)
Lancet
, vol.374
, pp. 41-42
-
-
Van, O.J.1
Kapur, S.2
-
41
-
-
84942512953
-
Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis
-
Vancampfort, D., Stubbs, B., Mitchell, A.J., De Hert, M., Wampers, M., Ward, P.B., et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatr. 14 (2015), 339–347.
-
(2015)
World Psychiatr.
, vol.14
, pp. 339-347
-
-
Vancampfort, D.1
Stubbs, B.2
Mitchell, A.J.3
De Hert, M.4
Wampers, M.5
Ward, P.B.6
-
42
-
-
84888134111
-
Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics
-
Wang, S.M., Han, C., Lee, S.J., Patkar, A.A., Masand, P.S., Pae, C.U., Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics. Clin. Neuropharmacol. 36 (2013), 223–238.
-
(2013)
Clin. Neuropharmacol.
, vol.36
, pp. 223-238
-
-
Wang, S.M.1
Han, C.2
Lee, S.J.3
Patkar, A.A.4
Masand, P.S.5
Pae, C.U.6
-
43
-
-
85034670008
-
The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis
-
Zhang, Y., Liu, Y., Su, Y., You, Y., Ma, Y., Yang, G., et al. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatr., 17, 2017, 373.
-
(2017)
BMC Psychiatr.
, vol.17
, pp. 373
-
-
Zhang, Y.1
Liu, Y.2
Su, Y.3
You, Y.4
Ma, Y.5
Yang, G.6
-
44
-
-
85021053158
-
Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials
-
Zheng, W., Li, X.H., Yang, X.H., Cai, D.B., Ungvari, G.S., Ng, C.H., et al. Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. Psychol. Med. 48 (2018), 72–81.
-
(2018)
Psychol. Med.
, vol.48
, pp. 72-81
-
-
Zheng, W.1
Li, X.H.2
Yang, X.H.3
Cai, D.B.4
Ungvari, G.S.5
Ng, C.H.6
|